Announcements Trials
Browse Landscape

Phase

Phase 2 62Phase 3 19Phase 1/2 13Phase NA 7Phase 1 6Phase 4 4Phase 2/3 2Phase EARLY_PHASE1 1

Status

Completed 6Active not recruiting 5Recruiting 3Unknown 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Large B-Cell, Diffuse 2Immunoproliferative Disorders 1

Interventions

Cisplatin 20Docetaxel 19Capecitabine 19Oxaliplatin 14Drug Therapy 14Cyclophosphamide 14Paclitaxel 13Fluorouracil 12Radiotherapy 11apatinib 9Gemcitabine 9Doxorubicin 9Decitabine 9Methotrexate 8Epirubicin 8Carboplatin 8sintilimab 6Etoposide 6camrelizumab 5anlotinib 5XELOX 5Sorafenib 5Radiation 5Pemetrexed 5Neoadjuvant Therapy 5Leucovorin 5Idarubicin 5Dexamethasone 5Cytarabine 5Busulfan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Unknown × Rituximab × Clear all
NCT02871869 2017-07-17

Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma

Xinjiang Medical University

Phase 2/3 Unknown
316 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT01277172 2011-01-14

TREND

Probiomed S.A. de C.V.

Phase 2/3 Unknown
54 enrolled
Lymphoid

Immunoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡